

1 **TITLE PAGE**

2 **Title: Markers Of Coagulation And Hemostatic Activation Identify COVID-19 Patients At**
3 **High Risk For Thrombotic Events, ICU Admission and Intubation**

4
5 **Authors:** Darwish Alabyad MS, Srikant Rangaraju MBBS, Michael Liu MD, Rajeel Imran MD,
6 Christine L. Kempton MD, MSc, Milad Sharifpour MD, Sara C. Auld MD, MSC, Manila Gaddh
7 MD, Roman Sniecinski MD, MSc, Cheryl L. Maier MD, PhD, Jeannette Guarner MD,
8 Alexander Duncan MD, and Fadi Nahab MD.

9
10 **Author Affiliations:**

- 11 1. Darwish Alabyad, MS
12 Morehouse School of Medicine, Atlanta, GA
13
- 14 2. Srikant Rangaraju M.B.B.S.
15 Department of Neurology
16 Emory University School of Medicine, Atlanta, GA
17
- 18 3. Michael Liu M.D.
19 Department of Neurology
20 Emory University School of Medicine, Atlanta, GA
21
- 22 4. Rajeel Imran, M.D.
23 Department of Neurology
24 Emory University School of Medicine, Atlanta, GA
25
- 26 5. Christine L Kempton M.D. M.Sc.
27 Department of Hematology and Medical Oncology
28 Emory University School of Medicine, Atlanta, GA
29
- 30 6. Milad Sharifpour M.D.
31 Department of Anesthesiology, Division of Critical Care Medicine
32 Emory University School of Medicine, Atlanta, GA
33
- 34 7. Sara C. Auld M.D., M.Sc.
35 Emory Critical Care Center
36 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine,
37 Emory University School of Medicine, Atlanta, GA
38 Department of Epidemiology, Emory University Rollins School of Public Health
39
- 40 8. Manila Gaddh M.D.
41 Department of Hematology and Medical Oncology
42 Emory University School of Medicine, Atlanta, GA
43
- 44 9. Roman Sniecinski M.D., M.Sc.
45 Department of Anesthesiology
46 Emory University School of Medicine, Atlanta, GA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

19
20
21
22
23
24
25
26
27
28
29
30
31
32

10. Cheryl L. Maier M.D., Ph.D.
Department of Pathology and Laboratory Medicine
Emory University School of Medicine, Atlanta, GA

11. Jeannette Guarner, MD
Department of Pathology and Laboratory Medicine
Emory University School of Medicine, Atlanta, GA

12. Alexander Duncan, MD
Department of Pathology and Laboratory Medicine
Emory University School of Medicine, Atlanta, GA

13. Fadi Nahab M.D. (*corresponding author*)
Department of Neurology & Pediatrics
Emory University, Atlanta, GA

Address: 1365 Clifton Road, Clinic B, Suite 2200, Atlanta, GA 30322

Fax: 404-778-3118

Phone: 404-727-1772

Email: fnahab@emory.edu

Total word count: 3231

1 **ABSTRACT**

2 **Background** – Coronavirus disease 2019 (COVID-19) has been associated with a coagulopathy
3 giving rise to venous and arterial thrombotic events. The objective of our study was to determine
4 whether markers of coagulation and hemostatic activation (MOCHA) on admission could
5 identify COVID-19 patients at risk for thrombotic events and other complications.

6 **Methods** – COVID-19 patients admitted to a tertiary academic healthcare system from April 3,
7 2020 to July 31, 2020 underwent standardized admission testing of MOCHA profile parameters
8 (plasma d-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex, and fibrin
9 monomer) with abnormal MOCHA defined as ≥ 2 markers above the reference. Prespecified
10 thrombotic endpoints included deep vein thrombosis, pulmonary embolism, myocardial
11 infarction, ischemic stroke, and access line thrombosis; other complications included ICU
12 admission, intubation and mortality. We excluded patients on anticoagulation therapy prior to
13 admission and those who were pregnant.

14 **Results** – Of 276 patients (mean age 59 ± 6.4 years, 47% female, 62% African American race)
15 who met study criteria, 45 (16%) had a thrombotic event. Each coagulation marker on admission
16 was independently associated with a vascular endpoint ($p < 0.05$). Admission MOCHA with ≥ 2
17 abnormalities ($n=203$, 74%) was associated with in-hospital vascular endpoints (OR 3.3, 95% CI
18 1.2-8.8), as were admission D-dimer ≥ 2000 ng/mL (OR 3.1, 95% CI 1.5-6.6), and admission D-
19 dimer ≥ 3000 ng/mL (OR 3.6, 95% CI 1.6-7.9). However, only admission MOCHA with ≥ 2
20 abnormalities was associated with ICU admission (OR 3.0, 95% CI 1.7-5.2) and intubation (OR
21 3.2, 95% CI 1.6-6.4), while admission D-dimer ≥ 2000 ng/mL and admission D-dimer ≥ 3000
22 ng/mL were not associated. MOCHA and D-dimer cutoffs were not associated with mortality.

1 Admission MOCHA with <2 abnormalities (26% of the cohort) had a sensitivity of 88% and
2 negative predictive value of 93% for a vascular endpoint.

3 **Conclusions** – Admission MOCHA with ≥ 2 abnormalities identified COVID-19 patients at
4 increased risk of ICU admission and intubation during hospitalization more effectively than
5 isolated admission D-dimer measurement. Admission MOCHA with <2 abnormalities identified
6 a subgroup of patients at low risk for vascular events. Our results suggest that an admission
7 MOCHA profile can be useful to risk-stratify COVID-19 patients.

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

1 INTRODUCTION

2 Coronavirus disease 2019 (COVID-19) has been widely associated with the development of a
3 systemic coagulopathy that is likely multifactorial in etiology.¹ COVID-19-associated
4 coagulopathy exhibits the classic components of Virchow's triad, and there are ongoing efforts to
5 better characterize the underlying pathophysiology of the hypercoagulable state in the setting of
6 COVID-19 infection.² Elevated levels of fibrin degradation products, particularly D-dimer, have
7 been used to predict venous thromboembolic events (VTE) and hypercoagulable states in various
8 disease states.^{3,4} Plasma D-dimer in COVID-19 patients was found to be a useful predictor of
9 VTE^{5,6} and thresholds of 2000 ng/mL or 3000 ng/mL have been suggested as indicators of
10 disease severity.^{7,8}

11 A biomarker panel called the markers of coagulation and hemostatic activation (MOCHA),
12 which includes plasma D-dimer, prothrombin fragment 1.2, thrombin-antithrombin complex and
13 fibrin monomer levels, has been shown to predict subsequent diagnosis of new malignancy,
14 VTE, and other hypercoagulable states in patients with cryptogenic stroke.^{9,10} A previous study
15 has also demonstrated that a MOCHA profile with < 2 marker abnormalities can effectively rule
16 out hypercoagulable states in patients with embolic stroke of undetermined source.¹¹

17 The objective of this study was to determine whether the admission MOCHA profile in
18 hospitalized COVID-19 patients could aid in risk stratification by identifying those patients at
19 low versus high risk of vascular thrombotic events, ICU admission, intubation and clinical
20 outcome more effectively than D-dimer alone.

21 METHODS

22 *Study Design and Setting*

1 Patients were prospectively identified from an admission census list that identified all COVID-19
2 patients admitted to four hospitals in Emory Healthcare, an urban, academic, tertiary healthcare
3 system in Atlanta, Georgia who had a MOCHA profile ordered on admission as part of a
4 standardized COVID-19 orderset from April 3, 2020 through July 31, 2020. Expert consensus of
5 a multidisciplinary working group recommended obtaining a MOCHA profile on all patients
6 admitted with a diagnosis of COVID-19. All patients were 18 years of age or older with
7 diagnosis of COVID-19 confirmed by PCR and had a MOCHA profile drawn within 72 hours of
8 hospitalization. For this analysis we excluded patients on outpatient anticoagulation therapy prior
9 to hospitalization due to the effect of anticoagulation on the MOCHA profile¹⁰ and pregnant
10 patients due to the lack of validated reference ranges. Electronic medical records were
11 retrospectively reviewed from admission through discharge or until the censor date of September
12 14, 2020 to identify venous and arterial thrombotic events. This study was approved by the
13 Emory University Institutional Review Board.

14 Patient demographics including age, sex, race, body mass index (BMI), and a history of
15 comorbidities including smoking, diabetes, hypertension, asthma, chronic obstructive pulmonary
16 disorder (COPD), human immunodeficiency virus (HIV) infection, end stage renal disease, atrial
17 fibrillation, prior VTE, coronary artery disease (CAD), stroke, and known active cancer were
18 collected. Total length of stay, length of intensive care unit (ICU) admission, length of
19 intubation, and final disposition were additionally recorded. Prespecified venous and arterial
20 endpoints monitored during hospitalization included deep vein thromboses (DVT), pulmonary
21 embolus (PE), myocardial infarction (MI), ischemic stroke, and dialysis or central line clots.
22 DVT was confirmed by duplex ultrasound and PE by CT, CT angiography or
23 ventilation/perfusion scans. MI was diagnosed as a troponin elevation and confirmation by a

1 board-certified cardiologist. Ischemic stroke was diagnosed by CT or MRI and confirmation by a
2 board-certified neurologist. Central access and renal replacement therapy circuit thrombosis were
3 determined based on chart documentation.

4

5 *Laboratory testing*

6 Admission MOCHA profiles were obtained within 72 hours of hospitalization and included
7 plasma levels of D-dimer (reference value <574 ng/mL), prothrombin fragment 1.2 (reference
8 range 65-288 pmol/L), thrombin-antithrombin complex (reference range 1.0-5.5 µg/L), and
9 fibrin monomer (reference value <7 µg/mL). All assays were performed in the hospital clinical
10 laboratories using 3.2% citrated plasma specimens. D-dimer levels were measured with high-
11 sensitivity latex dimer assay (Instrumentation Laboratories, Bedford, MA). Both prothrombin
12 fragment 1.2 and thrombin-antithrombin complexes were measured with the Enzygnost ELISA
13 kit (Siemens Healthcare, Tarrytown, NY). Soluble fibrin monomer levels were measured by
14 latex immunoassay (Stago, Parsippany, NJ).

15

16 *Statistical Analysis*

17 Descriptive statistics were used to summarize the data with results reported as percentages for
18 categorical variables. Means with standard deviations or medians with interquartile ranges were
19 reported for normally distributed and skewed variables, respectively. Comparisons between
20 means or medians of continuous variables were assessed with independent T-tests (two-tailed) or
21 by the Mann-Whitney U non-parametric test, respectively. Categorical variables were compared
22 with Pearson's chi-square and Fisher Exact tests. Significance for all descriptive analyses was set

1 at $p < 0.05$. Univariable analyses were conducted using binary logistic regression for binary
2 outcome variables (vascular endpoint, VTE, ICU admission, intubation and mortality).
3 Statistically significant predictors of these outcomes ($p < 0.10$) were then considered in
4 multivariable binary logistic regression analyses to identify independent outcome predictors
5 (adjusted $p < 0.05$). The association with thrombotic events within 14 days of admission was
6 additionally examined.

7 The frequency of D-dimer and MOCHA profile abnormalities were recorded and subsequently
8 analyzed in specific patient subsets, including those with ICU admission and intubation. The four
9 parameters of the MOCHA profile were independently assessed using receiver operator
10 characteristic (ROC) curve analysis in order to determine the area under the curve (AUC) as a
11 measure of discriminative power. Patients were stratified based on the number of elevated
12 MOCHA markers on admission. Sensitivity, specificity, positive predictive value (PPV), and
13 negative predictive value (NPV) were evaluated at different MOCHA and D-dimer cutoffs. This
14 was used to identify optimal thresholds for predicting thrombotic endpoints and to compare the
15 performance of admission MOCHA with admission D-dimer alone. Statistical analyses and
16 figures were generated using SPSS version 26 software.

17

18 **RESULTS**

19 *Descriptive Data*

20 A total of 297 confirmed COVID-19 patients were hospitalized during the study period and had
21 MOCHA profile within 72 hours of admission. After exclusion of 18 patients on outpatient
22 anticoagulation therapy and three pregnant patients, the analysis cohort included 276 patients.

1 The mean age of the cohort was 59 ± 6 years, 130 (47%) were female, and 160 (62%) were
2 African American. Median BMI was 30 (IQR: 26-37) kg/m^2 (Table 1). Common comorbidities
3 included hypertension (59%), obesity (n=140, 51%) and diabetes (n=108, 39%). The median
4 duration of hospitalization was 10 days (IQR: 6-19) including 159 patients (58%) admitted to the
5 ICU during their hospitalization, 90 (33%) who were intubated. Amongst the cohort, 241 (87%)
6 patients were discharged, 31 (11%) died and 4 (1%) remained hospitalized as of the censor date.

7 *Frequency of Vascular Events*

8 Vascular events were diagnosed in 45 patients (16%) (Table 2). Median number of days to
9 diagnosis of vascular event was 7 days (IQR: 2-15) from admission, with 32 (71%) of these
10 events occurring within the first two weeks of hospitalization. DVT occurred in 24 (8.7%)
11 patients, PE in 8 (2.9%), MI in 4 (1.5%), ischemic stroke in 5 (1.8%) and central or dialysis line
12 thrombosis in 7 (2.5%) patients; three patients (1%) developed more than one of these
13 complications.

14 Overall, 7 (2.5%) patients had no MOCHA abnormalities on admission, 66 (24%) had one
15 abnormality, 62 (23%) had two abnormalities, 69 (25%) had three abnormalities, and 72 (26.1%)
16 had abnormalities in all four MOCHA; 217 patients (79%) had an abnormal D-dimer on
17 admission, 51 (19%) had an admission D-dimer greater than 2000 ng/mL , and 40 (15%) had an
18 admission D-dimer greater than 3000 ng/mL . There were 115 (42%) patients who had an
19 elevated prothrombin fragment 1.2 level, 185 (67%) with an elevated thrombin-antithrombin
20 complex level, and 167 (61%) with elevated fibrin monomer levels. The frequency of thrombotic
21 events, ICU admission and intubation rates progressively increased with the number of MOCHA
22 abnormalities (Figure 1).

1

2 *Association of Admission MOCHA and D-dimer with Vascular Events*

3 In univariable analysis admission MOCHA ≥ 2 abnormalities, D-dimer ≥ 2000 ng/mL, D-dimer
4 ≥ 3000 ng/mL, BMI, and CAD were significantly associated with vascular events. However, in
5 multivariable analysis only MOCHA ≥ 2 (OR 3.3, 95% CI 1.2-8.8; $p=.02$), BMI (OR 1.04, 95%
6 CI 1.0-1.1; $p=.03$), D-dimer ≥ 2000 ng/mL (OR 3.1, 95% CI 1.5-6.6; $p=.003$), and D-dimer \geq
7 3000 ng/mL (OR 3.6, 95% CI 1.6-7.9; $p=.002$) were significant. In multivariable analysis,
8 factors associated with vascular events within 14 days of admission included male sex (OR 2.2,
9 95% CI 1.0-5.0; $p=.049$), MOCHA ≥ 2 abnormalities (OR 6.4, 95% CI 1.5-27.6; $p=.013$) and D-
10 dimer ≥ 2000 ng/mL (OR 2.5, 95% CI 1.1-5.9; $p=.03$).

11

12 *Association of Admission MOCHA and D-Dimer with ICU Admission, Intubation and Mortality*

13 In univariable analysis, admission MOCHA ≥ 2 abnormalities and a history of stroke were
14 significantly associated with ICU admission. However, in multivariable analysis, only admission
15 MOCHA ≥ 2 abnormalities was a significant predictor of ICU admission (OR 3.0, 95% CI 1.7-
16 5.2; $p=.0001$).

17 With regards to the risk of respiratory deterioration and intubation, BMI, history of hypertension,
18 and MOCHA ≥ 2 abnormalities were associated with intubation in univariable analysis. In
19 multivariable analysis, MOCHA ≥ 2 abnormalities (OR 3.2, 95% CI 1.6-6.4; $p=.001$) and BMI
20 (OR 1.04, 95% CI 1.0-1.1; $p=.017$) remained significant. D-dimer was not significantly
21 associated with either ICU admission or intubation.

1 In univariable analysis, admission MOCHA ≥ 2 abnormalities, history of stroke, hypertension,
2 diabetes and BMI were significantly associated with mortality. In multivariable analysis, only
3 BMI remained a significant predictor of mortality (OR 1.04, 95% CI 1.01-1.08; $p=0.02$).

4 *Value of Admission MOCHA and D-dimer in Predicting Vascular Events, VTE, ICU Admission,*
5 *and Intubation*

6 Sensitivity, specificity, PPV, and NPV at different MOCHA and D-dimer cutoffs are shown in
7 Table 3. A MOCHA profile with ≥ 2 abnormalities had a sensitivity of 89% (NPV 93%) for a
8 vascular thrombotic event through total hospitalization, 94% (NPV 97%) for a vascular
9 thrombotic event within two weeks of admission, and 96% (NPV 99%) for VTE within two
10 weeks of admission. D-dimer level ≥ 2000 ng/mL on admission had a sensitivity of 33% (NPV
11 87%) for a vascular thrombotic event through total hospitalization, sensitivity of 31% (NPV
12 90%) for a vascular thrombotic event within two weeks of admission and a sensitivity of 43%
13 (NPV 94%) for VTE within two weeks.

14 ROC curve analysis showed that all four MOCHA parameters were independent predictors of
15 any vascular endpoint ($p<.01$). However, the discriminative power for MOCHA was highest for
16 VTE within the first two weeks of admission, during which time D-dimer and thrombin-
17 antithrombin complex both had AUC 0.74, prothrombin fragment 1.2 had AUC 0.68 and fibrin
18 monomer AUC 0.62.

19

20 **DISCUSSION**

21 Our study provides systematic assessment of the admission MOCHA profile in hospitalized
22 COVID-19 patients and its association with vascular thrombotic events. While the frequency of

1 elevated D-dimer and prothrombin fragment 1.2 is similar to those reported in recent studies^{7,12},
2 our study is the first to report the frequency of thrombin-antithrombin complex and fibrin
3 monomer levels in hospitalized COVID-19 patients. While ≥ 2 abnormalities in the admission
4 MOCHA profile and D-dimer cutoffs were significantly associated with vascular thrombotic
5 events only the admission MOCHA profile was associated with subsequent ICU admission and
6 intubation whereas D-dimer cutoffs of ≥ 2000 ng/mL and ≥ 3000 ng/mL were not.

7 We assessed these four markers of coagulation and hemostatic activation given their prior
8 association with thrombotic events.⁹⁻¹¹ D-dimer is a marker of fibrinolysis as a byproduct of
9 fibrin degradation. Prothrombin fragment 1.2 is a marker of coagulation activation and released
10 during conversion of prothrombin to thrombin. Thrombin-antithrombin complex is a marker of
11 coagulation activation and a complex formed during thrombin formation. Fibrin monomer
12 (soluble fibrin) is a marker of coagulation activation and a byproduct of fibrinogen conversion to
13 fibrin.¹⁴

14 We found no association between admission MOCHA profile or admission D-dimer and
15 mortality, contrary to early studies from China which suggested that D-dimer was a predictor of
16 mortality in pooled analysis.¹³ There are several factors which may contribute to this difference:
17 1) our patients were all placed on prophylactic or therapeutic doses of anticoagulation therapy
18 according to our local guidelines which may have influenced overall mortality rates which are
19 lower in our cohort than other studies in the pooled analysis⁸; 2) the Chinese studies in this
20 pooled analysis were all retrospective cohorts and excluded patients who were still hospitalized
21 at the end of the study period contributing to a high risk of bias.¹³

22 Given current recommendations on the use of anticoagulation therapy in COVID-19 patients¹⁵,
23 we also sought to identify whether the MOCHA profile could identify a COVID-19 patient

1 subgroup that was at low risk for vascular thrombotic events. In our cohort, 26% of patients on
2 admission had 0 or 1 MOCHA abnormality with NPV of 93% for vascular thrombotic events and
3 NPV of 95% for VTE. These data suggest that this patient subgroup is at low risk for subsequent
4 thrombotic complications.

5 This study had several limitations. As the data was collected from a single academic healthcare
6 system, the generalizability of these findings needs to be studied in other settings. Our study
7 focused on admission coagulation markers to aid in early risk stratification for COVID-19
8 patients however it is unknown whether serial measurements and changes in values across time
9 may be better predictors. Lastly, our study did not assess whether the MOCHA profile could be
10 used to guide anticoagulation therapy and how that may impact overall thrombotic events and
11 clinical outcome.

12 In summary, the admission MOCHA profile of hospitalized COVID-19 patients is useful in
13 identifying hospitalized patients who are at increased risk for subsequent arterial and venous
14 thrombotic events and more effectively identifies patients requiring ICU admission and
15 intubation than admission D-dimer levels alone. Further investigation is needed to determine the
16 utility of the MOCHA profile to guide anticoagulation therapy.

17

18

19

20

21

1 **References:**

- 2 1. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique
3 characteristics of COVID-19 coagulopathy. *Crit Care*. 2020;24:360.
- 4 2. Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-
5 19) through the prism of Virchow's triad. *Clin Rheumatol*. 2020;39(9):2529-2543.
- 6 3. Karsy M, Azab MA, Harper J, et al. Evaluation of a D-Dimer Protocol for Detection of
7 Venous Thromboembolism. *World Neurosurg* 2020;133:e774-e783.
- 8 4. Shi A, Huang J, Wang X, et al. Postoperative D-dimer predicts venous thromboembolism
9 in patients undergoing urologic tumor surgery. *Urol Oncol*. 2018;36:307.
- 10 5. Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous
11 thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and
12 role of D-dimer as predictive factors. *J Thromb Thrombolysis*. 2020;50(1):211-216.
- 13 6. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients
14 with severe novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18(6):1421-1424.
- 15 7. Yao, Y., Cao, J., Wang, Q., Shi Q., Liu K., Luo Z., Chen X., Chen S., Yu K., Huang Z. *et*
16 *al.* D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a
17 case control study. *J Intensive Care* 2020;**8:1-11**.
- 18 8. Guidelines for the Prevention and Treatment of VTE in Critically Ill Patients with
19 COVID-19: [https://www.emoryhealthcare.org/ui/pdfs/covid/medical-](https://www.emoryhealthcare.org/ui/pdfs/covid/medical-professionals/COVID%20Emory%20VTE%20Guidelines%2021May2020.pdf)
20 [professionals/COVID%20Emory%20VTE%20Guidelines%2021May2020.pdf](https://www.emoryhealthcare.org/ui/pdfs/covid/medical-professionals/COVID%20Emory%20VTE%20Guidelines%2021May2020.pdf). Accessed
21 October 3, 2020.
- 22 9. Nahab F., Sharashidze V., Liu M., Rathakrishnan P., El Jamal S., Duncan A. , Hoskins
23 M., Marmarchi F., Belagaje S., Bianchi N. *et al.* Markers of coagulation and hemostatic

- 1 activation aid in identifying causes of cryptogenic stroke. *Neurology*. 2020; 94 (18)
2 e1892-e1899.
- 3 10. Ellis D, Rangaraju S, Duncan A, Hoskins M, Ali Raza S, Rahman H, Winningham M,
4 Belagaje S, Bianchi N, Mohamed G *et al*. Coagulation markers and echocardiography
5 predict atrial fibrillation, malignancy or recurrent stroke after cryptogenic stroke
6 [published correction appears in *Medicine (Baltimore)*. *Medicine (Baltimore)*.
7 2018;97(51):e13830.
- 8 11. Liu M, Rangaraju S, Ellis D, Duncan A, Belagaje S, Belair T, Henriquez L, Nahab F.
9 Abstract 28: Biomarkers of Coagulation and Hemostatic Activation in Post-Acute Period
10 Effectively Rule Out Hypercoagulable States in Patients with Embolic Stroke of
11 Undetermined Source. *Stroke* 2020;51:A27.
- 12 12. Al-Samkari H, Song, F, Van Cott, EM, Kuter, DJ, Rosovsky, R. Evaluation of the
13 prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). *Am J*
14 *Hematol*. 2020; 1– 7.
- 15 13. Sakka M, Connors JM, Hekimian G, Martin-Toutain I, Crichi B, Colmegna I, Bonnefont-
16 Rousselot D, Farge D, Frere C. *Journal de Medecine Vasculaire* 2020;45:268-274.
- 17 14. Dati F, Pelzer H, Wagner C. Relevance of Markers of Hemostasis Activation in
18 Obstetrics/Gynecology and Pediatrics. *Seminars in Thrombosis and Hemostasis* 1998;
19 24:443-448.
- 20 15. Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, Levi M, Samama
21 CM, Thachill J, Giannis D. Scientific and Standardization Committee communication:
22 Clinical guidance on the diagnosis, prevention, and treatment of venous

1 thromboembolism in hospitalized patients with COVID-19. *J Thromb*
2 *Haemost.* 2020;18:1859–1865.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

1 **Table 1. Patient characteristics and outcomes**

Characteristic	Cohort (n=276)
Demographics	
Age mean (SD)	59 (6.4)
Female, n (%)	130 (47)
Race, n (%)	
African American	160 (58)
Caucasian	45 (16)
Hispanic	44 (16)
Asian	9 (3)
Unspecified	18 (6.5)
Median BMI (IQR)	30 (26-37)
Hospitalization Details	
Median Length of Stay (IQR)	10 (6-19)
Intubation, n (%)	90 (33)
ICU Admission, n (%)	158 (57)
Discharge Disposition, n (%)	
Home	182 (67)
LTAC	16 (5.9)
Acute/Inpatient Rehab	8 (2.9)
Subacute Rehab	8 (2.9)
Nursing Home/ALF	27 (9.9)
Death	31 (11)

Comorbidities	
Smoker, ever, n (%)	60 (24)
Obese, n (%)	140 (51)
Diabetes, n (%)	108 (39)
Hypertension, n (%)	163 (59)
History of VTE, n (%)	3 (1.1)
Asthma, n (%)	25 (9.1)
COPD, n (%)	23 (8.3)
HIV, n (%)	4 (1.4)
ESRD on HD, n (%)	15 (5.4)
Atrial Fibrillation, n (%)	9 (3.3)
CAD, n (%)	25 (9.1)
Stroke, n (%)	19 (6.9)
Active Cancer, n (%)	8 (2.9)

1 Abbreviations: Body mass index (BMI). Intensive Care Unit (ICU). Long-term acute care
2 (LTAC). Assisted living facility (ALF).

3

4

5

6

7

1 **Table 2. Frequency of Outcomes**

Outcomes	Frequency*	
	Entire	Within 14 Days
	Hospitalization	
DVT, n (%)	24 (8.7)	17 (6.2)
PE, n (%)	8 (2.9)	7 (2.5)
MI, n (%)	4 (1.5)	4 (1.5)
Ischemic Stroke, n (%)	5 (1.8)	2 (0.7)
Line Clot, n (%)	7 (2.5)	5 (1.8)
Total Vascular Endpoints, n (%)	45 (16.3)	32 (11.6)

2 * 3 patients developed more than one vascular endpoint

3 DVT=deep vein thrombosis; PE=pulmonary embolus; MI=myocardial infarction

4

5

6

7


8

9

10

11

1 **Figure 1. Frequency of MOCHA abnormalities in patients with vascular endpoints,**
2 **intubation and ICU admission.**



3
4
5
6
7
8
9
10
11
12
13

- 1 **Table 3. Sensitivity, specificity, positive predictive value and negative predictive value for**
 2 **(A) admission MOCHA and (B) D-dimer cutoffs with vascular endpoints.**

A. Admission MOCHA abnormalities				
<i>1. Total vascular endpoint (n=45)</i>				
Threshold	Sensitivity	Specificity	PPV	NPV
≥0	100	0	16.3	
≥1	97.8	2.60	16.4	85.7
≥2	88.8	29.4	19.7	93.2
≥3	77.8	54.1	24.8	92.6
4	46.7	77.9	29.2	88.2
<i>2. Vascular endpoints <14 days from admission (n=32)</i>				
Threshold	Sensitivity	Specificity	PPV	NPV
≥0	100	0	11.6	
≥1	100	2.87	11.9	100
≥2	93.8	29.1	14.8	97.3
≥3	81.3	52.9	18.4	95.6
4	40.6	75.8	18.1	90.7
<i>3. Total VTE (n=31)</i>				
Threshold	Sensitivity	Specificity	PPV	NPV
≥0	100	0	11.2	
≥1	96.8	2.45	11.2	85.7
≥2	87.1	28.2	13.3	94.5
≥3	77.4	52.2	17.0	94.8
4	45.2	76.3	19.4	91.7
<i>4. VTE <14 days from admission (n=23)</i>				
Threshold	Sensitivity	Specificity	PPV	NPV
≥0	100	0	8.33	
≥1	100	2.77	8.55	100
≥2	95.7	28.5	10.8	98.6
≥3	87.0	52.2	14.2	97.8
4	47.8	75.9	15.3	94.1
B. Admission D-dimer (ng/mL)				
<i>1. Total vascular endpoint (n=45)</i>				
Threshold	Sensitivity	Specificity	PPV	NPV
≥2000 ng/mL	33.3	84.4	29.4	86.7

≥ 3000 ng/mL	28.9	88.3	32.5	86.4
-------------------	------	------	------	------

2. *Vascular endpoints <14 days from admission (n=32)*

Threshold	Sensitivity	Specificity	PPV	NPV
≥ 2000 ng/mL	31.3	83.2	19.6	90.2
≥ 3000 ng/mL	25.0	86.9	20.0	89.8

3. *Total VTE (n=31)*

Threshold	Sensitivity	Specificity	PPV	NPV
≥ 2000 ng/mL	38.7	84.1	23.5	91.6
≥ 3000 ng/mL	32.3	87.8	25.0	91.1

4. *VTE <14 days from admission (n=23)*

Threshold	Sensitivity	Specificity	PPV	NPV
≥ 2000 ng/mL	43.5	83.8	19.6	94.2
≥ 3000 ng/mL	34.8	87.4	20.0	93.6

- 1 MOCHA=markers of coagulation and hemostatic activation; PPV=positive predictive value;
- 2 NPV=negative predictive value; VTE=venous thromboembolism.